


The HER2 (ERBB2) Blueprint: What 'Activating' Really Means

This content was funded by Boehringer Ingelheim.


Oncol AMJ. 2026;3[Suppl x]:xx-xx. <https://doi.org/10.33590/oncolamj/C5244JH8>

THE HER2 BLUEPRINT



- The HER2 receptor comprises three key domains: ECD, TMD, and TKD.^{1,2}
- Each domain plays a distinct role in receptor function.^{1,2}
- The active form of the HER2 receptor is a dimer (homo- or heterodimer).^{1,2}

ACTIVATING MUTATIONS CAN OCCUR ANYWHERE IN THE HER2 RECEPTOR



★ Activating mutation

- HER2 activating mutations are not restricted to the TKD.²
- They can be found throughout the receptor: in the ECD, TMD, and TKD.²
- Regardless of the location, activating mutations can dysregulate receptor signaling and drive oncogenesis.^{3,4}

DIFFERENT LOCATIONS, SAME CONSEQUENCES

ECD mutations often lead to stabilization of active, homodimeric HER2 receptors.⁵


TMD mutations can stabilize the receptor in an active, open dimeric conformation.⁶

TKD mutations can shift the kinase domain from an inactive, closed state to an active, open conformation.⁷


HER2 activating mutations induce constitutive, ligand-independent TKD activation.^{4,5,8,9}

ACTIVATING MUTATIONS ARE CONSIDERED ONCOGENIC OR LIKELY ONCOGENIC

- Persistent phosphorylation triggers continuous activation of the MAPK and PI3K/AKT pathways, driving uncontrolled tumor cell growth.¹⁰



INHIBITING TKD ACTIVITY SUPPRESSES ONCOGENIC SIGNALING INDUCED BY HER2 ACTIVATING MUTATIONS



- Zongertinib is an irreversible TKI that selectively inhibits HER2 while sparing wild-type EGFR.¹¹⁻¹³
- It covalently binds the ATP-binding pocket within the TKD and can inhibit the kinase activity regardless of whether the activating mutation resides in the ECD, TMD, or TKD.^{12,14}

References

1. Yu J et al. Biomed Pharmacother. 2024;174:116522.
2. Bon G et al. Cancer Sci. 2024;115(7):2147-58.
3. Liu D et al. Cancer Res Commun. 2025;5(4):680-93.
4. Connell CM et al. ESMO Open. 2017;2(5):e000279.
5. Ishiyama N et al. Cancer Res. 2023;83(9):1531-42.
6. Pahuja KB et al. Cancer Cell. 2018;34(5):792-806.e5.
7. Wen W et al. J Mol Diagn. 2015;17(5):487-95.
8. Fan YX et al. J Biol Chem. 2008;283(3):1588-96.
9. Arkhipov A et al. Elife. 2013;2:e00708.
10. Pollock NI, Grandis JR. Clin Cancer Res. 2015;21(3):526-33.
11. Heymach JV et al. N Engl J Med. 2025;392(23):2321-33.
12. Wilding B et al. Cancer Discov. 2025;15(1):119-38.
13. Iqbal N, Iqbal N. Mol Biol Int. 2014;2014:852748.
14. Kurosaki T et al. Int J Mol Sci. 2025;26(21):10515.

Abbreviations:

AKT: protein kinase B; ECD: extracellular domain; EGFR: epidermal growth factor receptor; HER2: human epidermal growth factor receptor 2; TKD: tyrosine kinase domain; TKI: tyrosine kinase inhibitor; TMD: transmembrane domain.